Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) was up 1.8% on Thursday . The stock traded as high as C$2.23 and last traded at C$2.22. Approximately 181,842 shares changed hands during mid-day trading, an increase of 31% from the average daily volume of 138,904 shares. The stock had previously closed at C$2.18.
Cardiol Therapeutics Trading Up 1.8 %
The business’s 50 day simple moving average is C$2.69 and its 200-day simple moving average is C$2.85. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84. The stock has a market capitalization of C$155.13 million, a P/E ratio of -5.05 and a beta of 0.70.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Further Reading
- Five stocks we like better than Cardiol Therapeutics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- What is a Secondary Public Offering? What Investors Need to Know
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
